Document Type : Original Article


1 Human Genetics Division, Medical Biotechnology Department, National Institute of Genetics Engineering and Biotechnology, Tehran, Iran.

2 Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.

3 Personalized Medicine Research Center of AmitisGen, Tehran, Iran


Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is characterized by high blood sugar, insulin resistance, and relative lack of insulin.Diabetic retinopathy, a secondary microvascular complication of diabetes mellitus, is the leading cause of blindness. There is extensive evidence that the pathologic ocular angiogenesis in diabetic retinopathy is regulated by the vascular endothelial growth factor-A (VEGF-A).The single nucleotide polymorphism (SNP) C936T (rs3025039) of the VEGF gene has been investigated in relation to cancer, endometriosis, and age-related macular degeneration. The relationship between the rs3025039 VEGF gene polymorphism and the risk of type 2 diabetic retinopathy in 80 DT2 patients was examined. No significant association was found between polymorphism C936T and type 2 diabetes. It is recommended that this study be repeated on a larger population.


  1. Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H,Abildgaard N and Vangsted AJ: Vascular endothelial growthfactor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer 131: E636-E642,2012.
  2. Mandal RK, Yadav SS, Panda AK and Khattri S: Vascular endothelial growth factor 936 c>T polymorphism increased oral cancer risk: Evidence from a meta-analysis. Genet Test Mol Biomarkers 17: 543-547, 2013.
  3. Oliveira C, Lourenço GJ, Silva PM, Cardoso-Filho C, Favarelli MH, Gonçales NS, Gurgel MS and Lima CS: Polymorphisms in the 5'- and 3'-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics. Tumour Biol 32: 295-300, 2011.
  4. Eroglu A, Gulec S and Akar N: Vascular endothelial growthfactor C936T polymorphism in cancer patients with thrombosis. Am J Hematol 82: 174, 2007.
  5. Kim HW, Ko GJ, Kang YS, Lee MH, Song HK, Kim HK and Cha DR: Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients.Nephrology (Carlton) 14: 681-688, 2009.
  6. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I and Katayama S: A common polymorphism in the 5-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51: 1635-1639, 2002.
  7. Yang X, Deng Y, Gu H, Lim A, Altankhuyag A, Jia W, Ma K, Xu J, Zou Y, Snellingen T, et al: Polymorphisms in the vascularendothelial growth factor gene and the risk of diabetic retinopathy in Chinese Patients with type2 diabetes. Mol Vis17:3088-3096,2011.
  8. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL. Comparative analysis of vascular endothelial growth factor receptors on retinaland aortic vascular endothelial cells. Diabetes 1995; 44: 98-103.
  9. Resnick N, Collins T, Atkinson W, Bronthron DT, Dewey CF Jr.,Gimborne MA Jr. Platelet derived growth factor B chain promoter contains a cis-acting fluid shear stress responsive element. Proc Natt Acad Sci USA 1993; 90: 4592-5.
  10. Deguchi T, Hashiguchi T, Horinouchi S, Uto T, Oku H, Kimura K,Makisumi K and Arimura K: Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage. Diabet Med26:247-252,2009.
  11. Xaplanteris P, Vlachopoulos C, Baou K, Vassiliadou C, Dima I,Ioakeimidis N and Stefanadis C: The effect of p22(phox) 930A/G, A640G and C242T polymorphisms of NADPH oxidase on peripheral and central pressures in healthy, normotensive individuals. Hypertens Res 33: 814-818, 2010.
  12. Narne P, Ponnaluri KC, Singh S, Siraj M and Ishaq M: Relationship between NADPH oxidase p22phox C242T, PARP‑1 Val762Ala polymorphisms, angiographically verified coronary artery disease and myocardial infarction in South Indian patients with type 2 diabetes mellitus. Thromb Res 130: e259-e265, 2012.
  13. Naka KK, Papathanassiou K, Bechlioulis A, Kazakos N, Pappas K, Tigas S, Makriyiannis D, Tsatsoulis A and Michalis LK: Determinants of vascular function in patients with type 2 diabetes. Cardiovasc Diabetol 11: 127, 2012.
  14. Pirola L, Balcerczyk A, Okabe J and El-Osta A: Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 6: 665-675, 2010.
  15. Perkins BA, Orszag A, Ngo M, Ng E, New P and Bril V: Prediction of incident diabetic neuropathy using the monofilament examination A 4-year Prospective study. Diabetes Care33:1549-1554,2010.
  16. Feng Y, Schlösser FJ and Sumpio BE: The Semmes Weinsteinmonofilament examination is a significant predictor of the risk of foot ulceration and amputation in patients with diabetes mellitus. J Vasc Surg 53: 220-226, 2011.
  17. Di Castelnuovo A, Soccio M, Iacoviello L, Evangelista V, Consoli A, Vanuzzo D, Diviacco S, Carluccio M, Rignanese L and De Caterina R: The C242T polymorphism of the p22phox component of NAD(P)H oxidase and vascular risk. Two case-control studies and a meta-analysis. Thromb Haemost 99: 594-601, 2008.
  18. Kassab A and Piwowar A: Cell oxidant stress delivery and cell dysfunction onset in type 2 diabetes. Biochimie 94: 1837-1848, 2012.
  19. Goliasch G, Wiesbauer F, Grafl A, Ponweiser E, Blessberger H, Tentzeris I, Wojta J, Schillinger M, Huber K, Maurer G, et al: The effect of p22-PHOX (CYBA) polymorphisms on premature coronary artery disease (≤40 years of age). Thromb Haemost 105:529-534, 2011.